Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, PTFC increased levels of RNA and protein expression of Peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ in liver, fat and skeletal muscle of hyperlipidemia golden hamster, significantly.
|
31760082 |
2020 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results suggest that MO has protective potential against hyperlipidemia and steatosis, and the potential mechanism may have a close relation with activation of PPARα and inhibition of SREBP-1c.
|
30937936 |
2019 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that hepatic PPARα functions to control inflammation and liver triglyceride accumulation that prevent hyperlipidemia.
|
31483154 |
2019 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARα activators are clinically used for hyperlipidemia treatment.
|
31195146 |
2019 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Agents such as fenofibrate targeting PPARα-associated signaling pathways show promise as an alternative treatment of vascular dysfunction related to advanced age and hyperlipidemia.
|
31237119 |
2019 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, MG clearly alleviated serum TG and total cholesterol release; upregulated AKT, AMPK, and PPARα expression; suppressed SREBP-1c generation; and alleviated hepatic steatosis and dyslipidemia in Ty-induced hyperlipidemia mice.
|
29467759 |
2018 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor α (PPARα) is a therapeutic target for hyperlipidemia.
|
30041488 |
2018 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PPARα is highly expressed in liver and its agonists are widely used to treat hyperlipidemia.
|
29111315 |
2018 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-α (PPARα) is a master regulator of fatty acid oxidation whose activator is known to improve hyperlipidemia.
|
28404815 |
2017 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fenofibrate, a PPARα agonist, is the most widely prescribed drug for treating hyperlipidaemia.
|
28646549 |
2017 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-α (PPARα) is a therapeutic target for hyperlipidemia.
|
28084058 |
2017 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The decrease in LPC(16:0) in HL and CVD is consistent with its role in regulation of peroxisome proliferator-activated receptor alpha, an approved HL drug target that impacts the uptake and oxidation of fatty acids.
|
28157411 |
2017 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
|
28366492 |
2017 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings provide the first evidence that berberine is a potent agonist of PPARalpha and seems to be superior to fenofibrate for treating hyperlipidemia.
|
27100490 |
2016 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, curcumin alleviated the symptom of hyperlipidemia and hepatic steatosis via modulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and peroxisome proliferator-activated receptor-alpha as well as the activity of carnitine palmitoyltransferase 1.
|
26305715 |
2015 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this paper we demonstrate that bezafibrate, a PPAR pan agonist used for the treatment of patients with hyperlipidaemia reduces VLCFA levels in X-ALD fibroblasts.
|
22447153 |
2012 |
Hyperlipidemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Oral intake of Shan-Zha extract significantly improved hyperlipidemia in high fat diet-fed mice with an increase of PPARα expression in liver.
|
21823058 |
2011 |
Hyperlipidemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
|
21640707 |
2011 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both PPARα and PPARγ agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia.
|
21725906 |
2011 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, synthetic PPARalpha and PPARgamma ligands are currently used for treating hyperlipidemia and diabetes.
|
19866471 |
2010 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARalpha and PPARgamma agonists are already in clinical use for the treatment of hyperlipidemia and type 2 diabetes, respectively.
|
20026355 |
2010 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthetic PPAR agonists, such as fibrates and thiazolidinediones are already used to treat hyperlipidemia and diabetes mellitus, respectively.
|
18191967 |
2008 |
Hyperlipidemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands are medications used to treat hyperlipidaemia and atherosclerosis.
|
17888025 |
2007 |